AbbVie Inc.
AbbVie Discloses Impact of Acquired IPR&D and Milestones Expense on Q4 2025 Earnings
Summary
AbbVie Inc. reported that its GAAP and non-GAAP earnings for the fourth quarter of 2025 are expected to include an acquired IPR&D and milestones expense of $1.3 billion, negatively impacting both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share by $0.71. This expense has been factored into the company's updated full-year 2025 and fourth quarter 2025 adjusted diluted earnings per share guidance, which now range from $9.90 to $9.94 and $2.61 to $2.65, respectively. The final financial results are pending the completion of the company's financial statement closing procedures.
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents